Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan
暂无分享,去创建一个
S. Tagawa | M. Fontes | Daniel Vargas Pivato de Almeida | Clarissa Cavalin | Daniel Vargas Pivato de Almeida | Clarissa Cavalin
[1] A. Bardia,et al. Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] N. Agarwal,et al. TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens. , 2022, Journal of Clinical Oncology.
[3] C. Sternberg,et al. TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC). , 2022, Journal of Clinical Oncology.
[4] M. Meng,et al. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. , 2022, European urology oncology.
[5] A. Sartore-Bianchi,et al. The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives. , 2022, Cancer treatment reviews.
[6] Craig B. Davis,et al. Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial , 2021, Nature Medicine.
[7] M. Milowsky,et al. The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. , 2021, European urology.
[8] A. Patnaik,et al. 555TiP A first-in-human trial of the integrin beta-6-targeted antibody–drug conjugate, SGN-B6A, in patients with advanced solid tumors , 2021, Annals of Oncology.
[9] N. Agarwal,et al. 700P Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC) , 2021, Annals of Oncology.
[10] Toshio Shimizu,et al. 513O A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors , 2021, Annals of Oncology.
[11] Y. Cheng,et al. 514O An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors , 2021, Annals of Oncology.
[12] G. Getz,et al. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer , 2021, Cancer discovery.
[13] Sang-Hoon Yeon,et al. Enfortumab Vedotin in Advanced Urothelial Carcinoma. , 2021, The New England journal of medicine.
[14] A. Bardia,et al. Sacituzumab Govitecan For Metastatic Triple Negative Breast Cancer: Clinical Overview And Management Of Potential Toxicities. , 2021, The oncologist.
[15] Z. Gatalica,et al. Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers , 2021, Bosnian journal of basic medical sciences.
[16] Mark Laws,et al. Antibody–Drug Conjugates—A Tutorial Review , 2021, Molecules.
[17] N. Agarwal,et al. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Piccart,et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. , 2021, The New England journal of medicine.
[19] J. Berlin,et al. Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase 1/2 IMMU-132-01 Basket Trial. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] C. Sternberg,et al. TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy. , 2021 .
[21] T. Powles,et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. , 2021, The New England journal of medicine.
[22] S. Chandarlapaty,et al. Unlocking the potential of antibody–drug conjugates for cancer therapy , 2021, Nature Reviews Clinical Oncology.
[23] Jiyan Liu,et al. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma , 2020, Clinical Cancer Research.
[24] A. Scott,et al. Antibody–Drug Conjugates for Cancer Therapy , 2020, Molecules.
[25] Kedar S Vaidya,et al. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate , 2020, Molecular Cancer Therapeutics.
[26] S. Iacobelli,et al. Antibody-Drug Conjugates: The New Frontier of Chemotherapy , 2020, International journal of molecular sciences.
[27] Yahiya Y. Syed. Sacituzumab Govitecan: First Approval , 2020, Drugs.
[28] M. Milowsky,et al. Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. , 2020 .
[29] David C. Smith,et al. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] V. Miller,et al. Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions , 2020, BJU international.
[31] Juan Zhang,et al. Antibody–Drug Conjugates: A Comprehensive Review , 2019, Molecular Cancer Research.
[32] M. Galsky,et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] R. Huddart,et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.
[34] D. Goldenberg,et al. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan , 2019, mAbs.
[35] Li Zhou,et al. A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma. , 2019 .
[36] J. Hajdenberg,et al. Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study. , 2019, Journal of Clinical Oncology.
[37] Kendra S. Carmon,et al. Application of Immuno-PET in Antibody–Drug Conjugate Development , 2018, Molecular imaging.
[38] P. Dong,et al. B7H3 As a Promoter of Metastasis and Promising Therapeutic Target , 2018, Front. Oncol..
[39] D. Goldenberg,et al. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target , 2018, Oncotarget.
[40] D. Lamm,et al. LBA27 PHASE 3 STUDY OF VICINIUM IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: INITIAL RESULTS , 2018 .
[41] Z. Dai,et al. Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas , 2017, Cancer management and research.
[42] T. Powles,et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.
[43] A. Bardia,et al. Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics , 2017, Cancer.
[44] S. Alberti,et al. The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer , 2017, Oncotarget.
[45] R. Bourgon,et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.
[46] G. Sonpavde,et al. Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC) , 2016 .
[47] de Goeij,et al. Antibody-drug conjugates in cancer , 2016 .
[48] D. Stover,et al. Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker , 2016, Molecular Cancer Therapeutics.
[49] J. Hajdenberg,et al. Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. , 2016, Clinical genitourinary cancer.
[50] Nikolaos Diamantis,et al. Antibody-drug conjugates—an emerging class of cancer treatment , 2016, British Journal of Cancer.
[51] Paul Polakis,et al. Antibody Drug Conjugates for Cancer Therapy , 2016, Pharmacological Reviews.
[52] Edmund A. Rossi,et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) , 2015, Oncotarget.
[53] A. Nademanee,et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial , 2015, The Lancet.
[54] D. Goldenberg,et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. , 2015, Bioconjugate chemistry.
[55] R. Tripaldi,et al. The Trop-2 signalling network in cancer growth , 2013, Oncogene.
[56] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[57] M. Jewett,et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin. , 2012, The Journal of urology.
[58] Sheng Zhang,et al. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway , 2010, Molecular Cancer.
[59] M. Moasser. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis , 2007, Oncogene.
[60] A. Tzankov,et al. EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder , 2007, Journal of Clinical Pathology.
[61] K. Grigor,et al. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder , 2003, British Journal of Cancer.
[62] L. Kiemeney,et al. Epidemiology of Bladder Cancer , 1999, European Urology.